Engineering extracellular vesicles as novel treatment options: exploiting herpesviral immunity in CLL
Extracellular vesicles (EVs) are important mediators of cell–cell communication. Intriguingly, EVs can be engineered and thus exploited for the targeted transfer of functional proteins of interest. Thus, engineered EVs may constitute attractive tools for the development of novel therapeutic interven...
| Main Authors: | , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wiley
2019-12-01
|
| Series: | Journal of Extracellular Vesicles |
| Subjects: | |
| Online Access: | http://dx.doi.org/10.1080/20013078.2019.1573051 |
| _version_ | 1818914465991622656 |
|---|---|
| author | Kathrin Gärtner Manja Luckner Gerhard Wanner Reinhard Zeidler |
| author_facet | Kathrin Gärtner Manja Luckner Gerhard Wanner Reinhard Zeidler |
| author_sort | Kathrin Gärtner |
| collection | DOAJ |
| description | Extracellular vesicles (EVs) are important mediators of cell–cell communication. Intriguingly, EVs can be engineered and thus exploited for the targeted transfer of functional proteins of interest. Thus, engineered EVs may constitute attractive tools for the development of novel therapeutic interventions, like cancer immunotherapies, vaccinations or targeted drug delivery. Here, we describe a novel experimental immunotherapeutic approach for the adjuvant treatment of chronic lymphocytic leukaemia (CLL) based on engineered EVs carrying gp350, the major glycoprotein of Epstein–Barr virus (EBV), CD40L, a central immune accessory molecule and pp65, an immunodominant antigen of the human cytomegalovirus (CMV). We show that these engineered EVs specifically interact with malignant B cells from CLL patients and render these cells immunogenic to allogeneic and autologous EBV- and CMV-specific CD4+ and CD8+ T cells. Collectively, co-opting engineered EVs to re-target the strong herpesviral immunity in CLL patients to malignant cells constitutes an attractive strategy for the adjuvant treatment of a still incurable disease. Abbreviations: CLL: chronic lymphocytic leukaemia; EBV: Epstein-Barr virus; CMV: cytomegalovirus |
| first_indexed | 2024-12-19T23:46:49Z |
| format | Article |
| id | doaj.art-8dd3185ed0854d6d882d3438dc9f8d3e |
| institution | Directory Open Access Journal |
| issn | 2001-3078 |
| language | English |
| last_indexed | 2024-12-19T23:46:49Z |
| publishDate | 2019-12-01 |
| publisher | Wiley |
| record_format | Article |
| series | Journal of Extracellular Vesicles |
| spelling | doaj.art-8dd3185ed0854d6d882d3438dc9f8d3e2022-12-21T20:01:18ZengWileyJournal of Extracellular Vesicles2001-30782019-12-018110.1080/20013078.2019.15730511573051Engineering extracellular vesicles as novel treatment options: exploiting herpesviral immunity in CLLKathrin Gärtner0Manja Luckner1Gerhard Wanner2Reinhard Zeidler3Helmholtz Centre Munich German Research Centre for Environmental HealthLudwig-Maximilians-UniversitätLudwig-Maximilians-UniversitätHelmholtz Centre Munich German Research Centre for Environmental HealthExtracellular vesicles (EVs) are important mediators of cell–cell communication. Intriguingly, EVs can be engineered and thus exploited for the targeted transfer of functional proteins of interest. Thus, engineered EVs may constitute attractive tools for the development of novel therapeutic interventions, like cancer immunotherapies, vaccinations or targeted drug delivery. Here, we describe a novel experimental immunotherapeutic approach for the adjuvant treatment of chronic lymphocytic leukaemia (CLL) based on engineered EVs carrying gp350, the major glycoprotein of Epstein–Barr virus (EBV), CD40L, a central immune accessory molecule and pp65, an immunodominant antigen of the human cytomegalovirus (CMV). We show that these engineered EVs specifically interact with malignant B cells from CLL patients and render these cells immunogenic to allogeneic and autologous EBV- and CMV-specific CD4+ and CD8+ T cells. Collectively, co-opting engineered EVs to re-target the strong herpesviral immunity in CLL patients to malignant cells constitutes an attractive strategy for the adjuvant treatment of a still incurable disease. Abbreviations: CLL: chronic lymphocytic leukaemia; EBV: Epstein-Barr virus; CMV: cytomegalovirushttp://dx.doi.org/10.1080/20013078.2019.1573051extracellular vesiclesimmunotherapycllebvcmv |
| spellingShingle | Kathrin Gärtner Manja Luckner Gerhard Wanner Reinhard Zeidler Engineering extracellular vesicles as novel treatment options: exploiting herpesviral immunity in CLL Journal of Extracellular Vesicles extracellular vesicles immunotherapy cll ebv cmv |
| title | Engineering extracellular vesicles as novel treatment options: exploiting herpesviral immunity in CLL |
| title_full | Engineering extracellular vesicles as novel treatment options: exploiting herpesviral immunity in CLL |
| title_fullStr | Engineering extracellular vesicles as novel treatment options: exploiting herpesviral immunity in CLL |
| title_full_unstemmed | Engineering extracellular vesicles as novel treatment options: exploiting herpesviral immunity in CLL |
| title_short | Engineering extracellular vesicles as novel treatment options: exploiting herpesviral immunity in CLL |
| title_sort | engineering extracellular vesicles as novel treatment options exploiting herpesviral immunity in cll |
| topic | extracellular vesicles immunotherapy cll ebv cmv |
| url | http://dx.doi.org/10.1080/20013078.2019.1573051 |
| work_keys_str_mv | AT kathringartner engineeringextracellularvesiclesasnoveltreatmentoptionsexploitingherpesviralimmunityincll AT manjaluckner engineeringextracellularvesiclesasnoveltreatmentoptionsexploitingherpesviralimmunityincll AT gerhardwanner engineeringextracellularvesiclesasnoveltreatmentoptionsexploitingherpesviralimmunityincll AT reinhardzeidler engineeringextracellularvesiclesasnoveltreatmentoptionsexploitingherpesviralimmunityincll |